Gyre Therapeutics (NASDAQ:GYRE) Shares Up 6.6%

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) traded up 6.6% on Friday . The stock traded as high as $12.60 and last traded at $12.60. 44,962 shares traded hands during trading, a decline of 38% from the average session volume of 72,367 shares. The stock had previously closed at $11.82.

Gyre Therapeutics Trading Up 5.8 %

The company’s fifty day moving average price is $12.71 and its 200-day moving average price is $14.33.

Gyre Therapeutics (NASDAQ:GYRE) last issued its earnings results on Tuesday, August 13th. The company reported $0.01 EPS for the quarter. The firm had revenue of $25.23 million during the quarter. Sell-side analysts forecast that Gyre Therapeutics, Inc. will post -0.45 EPS for the current year.

Insider Transactions at Gyre Therapeutics

In other Gyre Therapeutics news, Director Nassim Usman sold 3,452 shares of the company’s stock in a transaction on Friday, June 28th. The shares were sold at an average price of $12.00, for a total value of $41,424.00. Following the sale, the director now directly owns 1,636 shares of the company’s stock, valued at $19,632. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 2.92% of the company’s stock.

Institutional Investors Weigh In On Gyre Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in GYRE. WINTON GROUP Ltd purchased a new position in shares of Gyre Therapeutics in the 2nd quarter valued at about $220,000. Bank of New York Mellon Corp purchased a new stake in shares of Gyre Therapeutics in the second quarter valued at approximately $218,000. Renaissance Technologies LLC purchased a new stake in shares of Gyre Therapeutics in the second quarter valued at approximately $166,000. Finally, Rhumbline Advisers acquired a new position in shares of Gyre Therapeutics during the 2nd quarter worth approximately $123,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.